Clinerion said that, via the partnership, its Patient Network Explorer will draw international clinical studies to India, benefiting the patients who need it most. "We all are aware that identifying eligible patients for a trial is a long and costly process,” said Dr Sanobar Parkar, Global Head Life Sciences, Alpha MD. “Many approvals or new drug launches in the market are delayed due to slow recruitment, thus costing a lot of money to sponsors. In addition, even patients who can benefit from participation in a clinical trial, especially in the oncology field, miss the opportunity due to lack of awareness of available study protocols among treating physicians. As a life science lead and a physician, I feel both these requirements are successfully met by the HIPAA and GDPR compliant Clinerion platform. By being part of this network, hospitals and patients in India will have access to global trials. This is necessary in making all alternatives available to patients and this will also eventually help in bringing new medicines to the Indian market and sooner.”
Ian Rentsch, Clinerion CEO, also commented on the partnership: “We are eager to support the clinical care of patients in India by leveraging the benefits of Clinerion’s Patient Network Explorer. With its strong presence in India, Alpha MD is well-placed to help us develop our site network there.”
International Hospitals & Healthcare Review is always keen to report on expansions and partnerships such as these, as we support and promote international patient care and the provision of care to those who need it most.